Purpose: The aim of this study was to investigate the effects of adrenomedullin (AM) and vascular endothelial growth factor (VEGF) on lung injury as a remote organ following skeletal muscle ischemia-reperfusion injury in a rat model. Materials and methods: Thirty-six Wistar rats were randomized into six groups (n=6). Laparotomy was performed in all groups under general anesthesia. Nothing else was done in Group S (Sham). Ischemia reperfusion group (Group I/R) underwent ischemia and reperfusion performed by clamping and declamping of the infrarenal abdominal aorta for 120 minutes, respectively. Group VEGF and Group AM received intravenous infusion of VEGF (0.8 μg/kg) or AM (12 μg /kg) respectively, without ischemia and reperfusion. Group IR+VEGF and Group IR+AM received intravenous infusion of VEGF (0.8 μg/kg) or AM (12 μg /kg) respectively immediately after 2 hours period of ischemia. At the end of reperfusion period. Lung tissue samples were taken for biochemical examination. Total oxidant status (TOS) and total antioxidant status (TAS) levels in lung tissue were determined by using a novel automated method. p<0.05 was considered as statistically signifi cant. Results: TOS levels were signifi cantly higher in Group I/R, when compared with groups S, AM and VEGF (p=0.004, p=0.011, p=0.017, respectively) and signifi cantly lower in groups I/R+AM and I/R+VEGF, when compared with Group I/R (p=0.018, p=0.006, respectively). TAS levels were signifi cantly higher in Group I/R, when compared with groups S, AM and VEGF (p=0.006 p=0.016, p=0.016, respectively) and signifi cantly lower in Group I/R+AM, when compared with Group I/R (p=0.016). Conclusion: These fi ndings indicate that AM and VEGF acted effectively on the prevention of lung injury induced by skeletal muscle ischemia-reperfusion injury in a rat model (Fig. 2, Ref. 30 ). Full Text in PDF www.elis.sk.
Ischemia / reperfusion (I/R) induced tissue injury is one of the most important problems in a number of surgical procedures including extremity revascularization, abdominal aortic surgery, replantation, transplantation and muscular fl ap reconstruction (1, 2) . Reperfusion of ischemic tissues results in both a local and a systemic infl ammatory response that, in turn, may result in widespread microvascular dysfunction and altered tissue barrier function (3) . Skeletal muscle I/R elicits oxidative stress and causes infl ammation in lung tissues that may lead to lung injury.
Adrenomedullin (AM) is a novel hypotensive peptide was discovered in 1993, in human pheochromocytoma by monitoring the elevating activity of platelet cAMP (4) . AM has a range of biological actions including vasodilatation, bronchodilatation, inhibition of apoptosis, cell growth, regulation of hormone secretion, natriuresis, antimicrobial and anti-infl ammatory effects (5, 6) .
Vascular endothelial growth factor (VEGF) is a potent angiogenic mitogen acting exclusively on endothelial cells (7) . Widespread distribution of VEGF and its specifi c receptors in the vasculature implies an important role for VEGF in maintenance of normal vascular function and development (8) . It has been demonstrated that VEGF stimulates nitric oxide release from vascular endothelial cells (9, 10) .
In this experimental study, we aimed to evaluate the oxidative effects of AM and VEGF on lung injury induced by skeletal muscle I/R.
Materials and methods

Experimental groups
Thirty-six adult Wistar-albino rats, weighing 200 to 250 g were used in this study. Rats were housed in cages at an average temperature of 22 °C in a light dark cycle-controlled environment with free access to food and tap water. The protocols of this experi-mental study were approved by the Animal Ethics Committee of Gazi University. All animals received human care in compliance with the "Principles of Laboratory Animal Care" formulated by the National Society for Medical Research and the "Guide for the Care and the Use of Laboratory Animals" prepared by the National Academy of Science and published by the National Institutes of Health (NIH publication no. 85-23, revised in 1985).
Study design
Rats were randomized into six groups (n=6/group). The sham group (Group S) underwent midline laparotomy and dissection of the infrarenal abdominal aorta (IAA) without cross-clamping; ischemia reperfusion group (Group I/R) underwent laparotomy and cross-clamping of the IAA for 120 minutes and then 120 minutes of reperfusion; Group VEGF and Group AM underwent laparotomy and received intravenous infusion of VEGF (0,8 μg/kg) or AM (12 μg /kg) respectively, without ischemia and reperfusion; Group I/ R+VEGF and Group I/R+AM received intravenous infusion of VEGF (0,8 μg/kg) or AM (12 μg /kg), respectively, immediately after 120 minutes of ischemia.
Aortic occlusion and ıschemia reperfusion
Rats were anesthetized with ketamine hydrochloride (Ketalar, 50 mg/kg, intramuscularly, Parke-Davis, Eczacibasi, Istanbul, Turkey) and xylazine hydrochloride (Alfazyne, 2 %, Ege Vet, Izmir, Turkey). Anesthesia was maintained by an additional muscular injection of ketamine hydrochloride and xylazine hydrochloride. The surgical procedures were performed while the rats were placed in a supine position under a heating lamp. The abdomen was shaved, the skin was prepared aseptically and a midline laparotomy was performed. The abdominal aorta was exposed and clamped using an atraumatic microvascular clamp. The aortic occlusion was confi rmed by the loss of the distal arterial pulsation. The skin incision was closed and covered with a plastic wrap to maintain the body temperature and fl uid balance. After 120 minutes of ischemia, the microvascular clamp was removed and lower extremities were reperfused for 120 minutes. At the end of the reperfusion period, all rats were killed under anesthesia and left lung was harvested for biochemical analyses.
Biochemical examination
Blood samples were obtained after induction of anesthesia and at the end of the surgery. The samples centrifugated at 3000 revolutions per minute for 10 minutes to separate plasma and then blood samples were stored at −80 °C until analysis.
Measurement of serum total oxidant status (TOS)
Plasma total oxidant status (TOS) levels were determined using a commercially available kit, developed by Erel (11) (REL assay diagnostics, Mega Tip, Gaziantep, Turkey). In this method, the oxidants present in the sample oxidize the ferrous ion-o-dianisidine complex to ferric ion. The oxidation reaction is enhanced by glycerol molecules, which are abundantly present in the reaction medium. The ferric ion produces a colored complex with xylenol orange in an acidic medium. The color intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide, and the results are expressed as μmol H 2 O 2 equivalent/L. Hydrogen peroxide and other derivatives of peroxides, produced physiologically in organisms and occurring in higher concentrations under some pathologic conditions, diffuse into plasma. The level of total peroxide was measured and expressed as TOS in this study.
Measurement of serum total antioxidant status (TAS)
Plasma total antioxidant status (TAS) levels were determined using a commercially available kit developed by Erel (REL assay diagnostics, Mega Tip, Gaziantep, Turkey) (12) . In this method, hydroxyl radical, which is the most potent radical, is produced via Fenton reaction. In the classical Fenton reaction, the hydroxyl radical is produced by mixing of ferrous ion solution and hydrogen peroxide solution. In the most recently developed assay by Erel, same reaction is used. In the assay, ferrous ion solution, which is present in the Reagent 1, is mixed by hydrogen peroxide, which is present in the Reagent 2. The sequentially produced radicals such as brown-colored dianisidinyl radical cation, produced by the hydroxyl radical, are also potent radicals. In this assay, antioxidative effect of the sample against the potent free radical reactions, which is initiated by the produced hydroxyl radical, is measured. The assay has got excellent precision values, which are lower than 3%. The results are expressed as mmol Trolox equivalent.
Statistical analyses
Statistical Package for the Social Sciences (SPSS, Chicago, IL, USA) 17.0 program was used for statistical analysis. KolmogorovSmirnov test was used for the comparisons to determine the distribution of all variable groups. Variations in TOS and TAS levels were assessed by using Kruskal-Wallis test. Bonferroni adjusted Mann-Whitney U test was used after signifi cant Kruskal-Wallis to determine which group differs from the other. Results were expressed as mean± standard deviation (mean ± SD). Statistical signifi cance was set at a p value <0.05.
Results
There was a statistically signifi cant difference among the groups, when they were compared among themselves by means of TOS levels in lung tissue (p=0.017). TOS levels were significantly higher in Group I/R, when compared with groups S, AM and VEGF (p=0.004, p=0.011, p=0.017, respectively). TOS levels were found to be signifi cantly lower in groups I/R+AM and I/R+VEGF, when compared with Group I/R (p=0.018, p=0.006, respectively) (Fig. 1) .
A statistically signifi cant difference was found among the groups, when they were compared among themselves for TAS levels in lung tissue (p=0.012). TAS levels were signifi cantly higher in Group I/R, when compared with groups S, AM and VEGF (p=0.006 p=0.016, p=0.016, respectively). TAS levels were found to be signifi cantly lower in Group I/R+AM, when compared with Group I/R (p=0.016). Figure 2 shows the levels of TAS in study groups.
Discussion
Temporary aortic cross-clamping is accompanied by I/R injury and a systemic infl ammatory response syndrome that can lead to non-cardiogenic pulmonary oedema, or acute respiratory distress syndrome in abdominal aortic surgery (13, 14) . In the development of lung injury, the excessive generation of reactive oxygen radicals, polymorphonuclear sequestration in pulmonary microvasculature, increased endothelial permeability and interstitial edema have been suggested (15) . Restoration of the blood supply to the ischemic tissue results in generation of reactive oxygen species (ROS). Excessive production of ROS causes lipid peroxidation in cell membranes and oxidative damage to DNA and proteins (16) . A number of agents, such as N-acetylcystein, calcium dobesilate, aprotinin, erdosteine or magnesium sulfate have been proposed to be useful against lung injury induced by I/R (17) (18) (19) (20) (21) .
AM is a potent vasodilating peptide that is expressed in tissues relevant to cardiovascular and renal function, such as the heart, kidney, aorta, lung and brain (22) . Several mechanisms have been proposed for the protective effects of AM. It has been shown to possess a number of biological effects in addition to its well-known vasoactive activity (23) . These include cell proliferation, differentiation, and oxidative stress-induced cell death inhibition (24) (25) (26) .
Talero et al suggested that AM treatment prevented the formation of malondialdehyde, an indicator of lipid peroxidation, which refl ects reduced oxidative stress. They have indicated that, AM has potential anti-infl ammatory actions in the development of experimental pleurisy, attenuating nuclear factor-κB activation, and the expression of proinfl ammatory cytokines and inducible nitric oxide synthase enzyme (27) . These effects may explain the decrease in neutrophil migration and oxidative stress during the course of the infl ammatory response. Adrenomedullin has also been shown to play important roles in cardiovascular and renal diseases via suppression of oxidative stress production through activation of second messengers cAMP and nitric oxide cGMPdependent signaling pathways (22) .
VEGF is a potent regulator of vascular permeability, a key player in angiogenesis, and a survival factor for endothelial cells. Mura et al suggested that VEGF produced in type II alveolar epithelial cells plays an important role in maintaining alveolar structure in adults and in mediating acute lung injury by regulating pulmonary permeability and infl ammation (28) .
Considering the benefi cial effects of AM and VEGF, the present study investigated the anti-oxidative effects of these agents in a model of skeletal muscle I/R-induced acute lung injury in rats. In this study, we have used a novel measurement method to evaluate the extent of oxidative stress in rat lungs after skeletal muscle I/R. This provides a useful method for the rapid evaluation of the TAS and TOS, which are valuable parameters in conditions involving oxidative stress. TOS indicates the total oxidative products in tissue. Oxidative products such as ROS, reactive nitrogen species, hydrochloric acid, malondialdehyde, and lipid peroxides constitute TOS (11) . In our study, TOS levels signifi cantly increased after aortic I/R. We also found that I/R plus AM and I/R plus VEGF signifi cantly reduced the levels of TOS. TAS levels signifi cantly increased in Group I/R+AM. Also I/R plus VEGF increased the levels of TAS, but this increase was not statistically signifi cant. Our fi ndings are consistent with previous papers reporting the antioxidant effects of AM on animal models of remote organ injury induced by aortic I/R (16, 29, 30) . The mechanism of protective effect of AM against lung injury cannot be explained by only its antioxidative effect, since I/R injury is a complex process. Histopathologic and antiinfl ammatory effects of the peptid should also be investigated. The regulator and angiogenetic effects of VEGF have been suggested in previous studies (7, 10, 28) . We have hypothesized that it may also have an antioxidative effect on lung injury to some extent. Our fi ndings need to be supported by further studies evaluating different oxidative parameters.
Conclusion
The results of this study demonstrate that administration of AM and VEGF have antioxidative effects against lung injury induced by skeletal muscle I/R. However, further studies also evaluating histological and other biochemical parameters are required to confi rm this fi nding and to elucidate the exact mechanism of action before clinical use. 
